<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Symptom Advice .com &#187; surgical margins</title>
	<atom:link href="http://symptomadvice.com/tag/surgical-margins/feed/" rel="self" type="application/rss+xml" />
	<link>http://symptomadvice.com</link>
	<description></description>
	<lastBuildDate>Tue, 29 May 2012 22:17:13 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>UroToday &#8211; Renal Cancer</title>
		<link>http://symptomadvice.com/urotoday-renal-cancer/</link>
		<comments>http://symptomadvice.com/urotoday-renal-cancer/#comments</comments>
		<pubDate>Fri, 27 Jan 2012 16:34:16 +0000</pubDate>
		<dc:creator>Symptom Advice</dc:creator>
				<category><![CDATA[kidney symptoms]]></category>
		<category><![CDATA[clinical variables]]></category>
		<category><![CDATA[kaplan meier]]></category>
		<category><![CDATA[male gender]]></category>
		<category><![CDATA[surgical margins]]></category>
		<category><![CDATA[tumor location]]></category>

		<guid isPermaLink="false">http://symptomadvice.com/urotoday-renal-cancer/</guid>
		<description><![CDATA[INTRODUCTION: Tumor recurrence following nephron-sparing surgery (NSS) &#102;&#111;&#114; renal carcinoma is &#097; major concern. The aim of &#116;&#104;&#105;&#115; retrospective study was &#116;&#111; assess the rate, patterns, and predictors of tumor recurrence &#105;&#110; patients following NSS &#102;&#111;&#114; renal cancer. METHODS: Between 1993 and 2008, 229 patients underwent NSS via flank incision &#102;&#111;&#114; renal cell carcinoma. Patients [...]]]></description>
			<content:encoded><![CDATA[<p></p><p><img src="" style="float:left;clear:both;margin:0 15px 15px 0" />
<p><strong>INTRODUCTION:</strong> Tumor recurrence following nephron-sparing surgery (NSS) &#102;&#111;&#114; renal carcinoma is &#097; major concern. The aim of &#116;&#104;&#105;&#115; retrospective study was &#116;&#111; assess the rate, patterns, and predictors of tumor recurrence &#105;&#110; patients following NSS &#102;&#111;&#114; renal cancer.</p>
<p><strong>METHODS:</strong> Between 1993 and 2008, 229 patients underwent NSS via flank incision &#102;&#111;&#114; renal cell carcinoma. Patients &#119;&#105;&#116;&#104;&#111;&#117;&#116; metastases at diagnosis (using CT and bone scan) were included &#105;&#110; the outcome analysis. Categorical variables were compared &#119;&#105;&#116;&#104; the Fisher-Irwin exact test. Kaplan-Meier was &#117;&#115;&#101;&#100; &#116;&#111; determine the probability of &#111;&#118;&#101;&#114;&#097;&#108;&#108; survival and probability of recurrence curves; significance was tested &#119;&#105;&#116;&#104; the log-rank. The Cox hazard survival model was &#117;&#115;&#101;&#100; &#116;&#111; identify &#119;&#104;&#101;&#116;&#104;&#101;&#114; any of the demographic or clinical variables were predictive of the probability of recurrence.</p>
<p><strong>RESULTS:</strong> During &#097; &#109;&#101;&#097;&#110; (SD) follow-up time of 45 (34) months, tumor recurrence was observed &#105;&#110; 13 patients (5.6%). &#109;&#101;&#097;&#110; follow-up time &#102;&#111;&#114; detection of oncological failure was 51 months. All patients &#119;&#105;&#116;&#104; oncological failure were males, &#119;&#105;&#116;&#104; &#097; &#109;&#101;&#097;&#110; age of 61 years (median 58; range, 51-74 years). The average size of the enucleated lesion was 5 cm (range, 4-7 cm). Intraoperative frozen sections and postoperative pathological examination of the surgical margins were negative &#105;&#110; all cases. Predictors of oncological failure included: warm ischemia time &gt; 20 minutes (P = .012), tumor size ? 4 cm (P = .001), central tumor location (P = .015), multifocal tumors (P = .001), and male gender (P = .01). The probability of &#111;&#118;&#101;&#114;&#097;&#108;&#108; disease recurrence at 12 and 60 months was 1.8% and 4.0%, &#114;&#101;&#115;&#112;&#101;&#099;&#116;&#105;&#118;&#101;&#108;&#121;. The &#111;&#118;&#101;&#114;&#097;&#108;&#108; cancer-specific survival rate was 93.8%. The 12-month and 60-month metastasis-free survival rates were 99.1% and 98.4%, &#114;&#101;&#115;&#112;&#101;&#099;&#116;&#105;&#118;&#101;&#108;&#121;. Recurrence was &#100;&#117;&#101; &#116;&#111; surgeon-related and tumor-related patterns.</p>
<p><strong>CONCLUSIONS:</strong> NSS is an effective surgery &#119;&#105;&#116;&#104; satisfactory long-term cancer control. Predictors of recurrence were consistent &#119;&#105;&#116;&#104; previous literature &#101;&#120;&#099;&#101;&#112;&#116; &#102;&#111;&#114; warm ischemia time &gt; 20 minutes (noted &#102;&#111;&#114; the &#102;&#105;&#114;&#115;&#116; time). Reasons &#102;&#111;&#114; cancer relapse include seeding during surgery, residual disease, distant dissemination, and &#110;&#101;&#119; tumor growth. Careful tumor handling and extensive perirenal &#102;&#097;&#116; resection are &#119;&#105;&#116;&#104;&#105;&#110; the surgeon&#8217;s control and may reduce failure rates.</p>
<p><strong>KEYWORDS:</strong> Renal cell carcinoma; Nephron-sparing surgery; Cancer recurrence.</p>
<p><strong>CORRESPONDENCE:</strong> CORRESPONDENCE: Sarel Halachmi MD, Department of Urology, Bnai Zion Medical Center, 47 Golomb St. 31048, Haifa, Israel (il).</p>
<p><strong>CITATION</strong>: Urotoday Int J. 2010 Jun;3(3). doi:10.3834/uij.1944-5784.2010.12.17</p>
<p><strong>ABBREVIATIONS AND ACRONYMS</strong>: NSS, nephron-sparing surgery; RCC, renal cell carcinoma.</p></p>
]]></content:encoded>
			<wfw:commentRss>http://symptomadvice.com/urotoday-renal-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
